Find Funding Opportunities

This FOA aims to address three major goals. The first is to utilize single-cell(-nuc) technologies to characterize the changes to cell identity, number, and/or morphology within a defined brain region, the hippocampus, from subjects experiencing mild cognitive impairment (MCI). Specifically, applicants will collect single-cell(-nuc) transcriptomic and epigenetic data from neuronal, glial, or vascular cells using MCI autopsy brains. Next, applicants will propose a data coordination center to collect single-cell(-nuc) omics data generated using diverse tissue sources and various, well-documented tissue preparation techniques from each group in the consortium. This data will be used to identify critical factors for robust and accurate single-cell(-nuc) omics analysis. Finally, this FOA will prompt applicants to coordinate their single-cell(-nuc) data sets with those produced by the BRAIN Initiatives human cell census. The aim is to enable investigators to utilize BRAIN cell census data sets generated from the analysis of healthy human brain and harmonize single-cell(-nuc) data sets from ADRD human brains with the BRAIN Initiative cell type registry.

More than 25 million Americans suffer from daily chronic pain, a highly debilitating medical condition that is complex and difficult to manage. In recent decades, there has been an overreliance in the prescription of opioids for chronic pain despite their poor ability to improve function and high addiction liability. This contributed to a significant and alarming epidemic of opioid overdose deaths and addictions. Innovative scientific solutions to develop alternative pain treatment options are thus critically needed. Through targeted research efforts, the NIH HEAL Initiative aims to support the development of safe and effective devices to treat pain with little or no addiction liability. This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PD/PIs to investigate the mechanism of action of device-based pain relief with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Program teams are expected to accomplish goals that require considerable synergy and collaborative interactions. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider objectives that will produce major advances in the field of device-based pain relief.

The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. This Funding Opportunity Announcement (FOA) solicits applications for production and phenotyping centers that will make maximum progress toward completion of KOMP2 in a final five-year project period. The specific objectives are to generate approximately 1,200 mutant mouse lines using CRISPR/Cas9 technology, perform a series of phenotyping assays, cryopreserve germplasm, and make mice and data readily available to the research community. This is a limited competition RFA. Only recipient organizations funded under (RFA-RM-15-017) are eligible to apply.

The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The goal of this FOA is to provide informatics support to NIH funded projects that are performing high-throughput broad-based phenotyping of mouse knock-out (KO) lines (see RFA-HG-21-036) and to coordinate with international efforts so as to integrate all data into a common database under the auspices of the International Mouse Phenotyping Consortium (IMPC). The Data Coordination Center and Database (DCCDB) will perform the validation, analysis, annotation, visualization, and dissemination of the phenotype data from the knockout lines. Curation will require integration with other data sources. This is a limited competition RFA. Only recipient organizations funded under (RFA-RM-15-016) are eligible to apply.

This Notice encourages eligible awardees in the BRAIN Initiative community to apply for administrative supplements in response to PA-21-071, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-18-210) and encourages institutions to diversify their populations by enhancing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences.

The purpose of this request for administrative supplements to current NIH-fundedstudies is to encourage clinical and translational research that will increase our understanding of the prevalence, psychological variables, and response to therapy in those individuals with multiple chronic overlapping pain conditions (COPCs). Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one pain disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the characteristics of overlapping pain conditions, the progression of these conditions, and therapeutic approaches best suited for treating individuals with COPCs. Research efforts in chronic pain conditions have focused on single disorders or types of pain such as neuropathic and inflammatory pain. These research efforts have generated a substantial body of information advancing our understanding of the underlying mechanisms of pain onset and development, the transition from acute to chronic pain, and therapeutic targets for treating acute and chronic pain. Over the past twenty years reports have documented the presence of more than one chronic pain condition in subjects with pain. Studies have identified overlap between a number of chronic pain conditions, including lower back pain, fibromyalgia (FM), vulvodynia, endometriosis, functional gastrointestinal disorders such as irritable bowel syndrome (IBS), temporomandibular joint disorder (TMD), migraine, tension headache, low back pain, and urologic chronic pelvic pain syndromes (UCPPS). These results suggest that chronic pain conditions may not be localized conditions but may share symptoms and mechanisms that involve a general central nervous system dysfunction as well as disorder-specific symptoms.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and partnering Institutes invite applications for the Autism Centers of Excellence: Networks Program, hereafter termed ACE Networks. Each ACE Network will consist of a multi-site project focusing on a specific topic of research for R01 support through this FOA. Each ACE Network will submit one R01 application that includes sub-awards to the collaborating sites. A companion FOA (RFA-HD-22-008) invites applications for ACE Centers supported by the P50 mechanism.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and partnering Institutes invite applications for the Autism Centers of Excellence: Centers Program, hereafter termed ACE Centers. The P50 mechanism allows for integrative, multi-disciplinary, coordinated programs of research that demonstrate cohesion and synergy across research projects and cores. A companion FOA (RFA-HD-22-007) invites applications for ACE Networks supported by the R01 mechanism.

The NIH Blueprint for Neuroscience Research, with participating NIH Institutes and Centers (ICs), intends to promote the new Blueprint MedTech program by publishing a Funding Opportunity Announcement (FOA) to solicit applications to establish incubator hubs to provide medical device developers (innovators) with resources to support development of human-grade prototypes. The FOA intends to utilize the U54 activity code and is expected to be published in Summer 2021 with an expected application due date in Fall 2021. Incubator hubs will coordinate and manage resources for the Blueprint MedTech program, working as a consortium to provide: (1) infrastructure for identifying the most promising technologies, (2) the distribution of sub-award funding for innovators and resources to support product definition (e.g., needs assessment, product design, prototype development), and (3) access to relevant expertise (e.g., scientific, design, business development, and project management). Details of the planned program are provided below. This Notice is being provided for informational purposes to allow potential applicants additional time to develop responsive applications and meaningful collaborations. NIH reserves the right to modify the scope and objectives as described in this Notice. Final scope, objectives, and requirements will be set forth in the published FOAs.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and limited-size clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and effectivenesting, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the FDA or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. SBCs developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see: https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medte…